Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
$3.36
+5.0%
$3.04
$2.07
$4.20
$103.07M0.39105,031 shs181,718 shs
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$13.14
+11.9%
$0.00
$11.06
$63.00
$229.61M1.52106,004 shs222,371 shs
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$2.11
+16.1%
$1.69
$1.15
$3.38
$12.68M-0.3422,569 shs128,413 shs
Synlogic, Inc. stock logo
SYBX
Synlogic
$1.51
+14.4%
$1.19
$0.90
$1.88
$15.44M0.5519,068 shs228,915 shs
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
$1.30
$1.30
$0.25
$1.40
$70.12M1.32515,333 shsN/A
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
+5.00%+6.67%-10.40%+23.53%+4.35%
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
+11.93%-11.16%-98.29%-98.29%-98.29%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
+16.07%+22.95%+18.26%+31.56%-37.16%
Synlogic, Inc. stock logo
SYBX
Synlogic
+14.39%+21.77%+24.79%+42.45%-3.21%
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
2.9482 of 5 stars
3.63.00.00.02.53.30.0
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
3.1964 of 5 stars
3.80.00.03.72.81.70.6
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
4.226 of 5 stars
3.05.00.04.62.00.01.3
Synlogic, Inc. stock logo
SYBX
Synlogic
1.1518 of 5 stars
0.03.00.00.03.31.70.6
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
3.25
Buy$9.00167.86% Upside
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
3.50
Strong Buy$25.6795.33% Upside
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
2.00
Hold$5.00137.53% Upside
Synlogic, Inc. stock logo
SYBX
Synlogic
0.00
N/AN/AN/A
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NERV, ZYNE, SYBX, ANIX, and CBIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/14/2025
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$27.00
6/25/2025
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$28.00
6/20/2025
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/18/2025
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$22.00
6/10/2025
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
5/29/2025
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
$210K515.36N/AN/A$0.59 per share5.69
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$10K25,688.70N/AN/A$8.24 per share1.59
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/A$0.24 per share8.68($3.67) per shareN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
$10K1,766.70N/AN/A$1.09 per share1.39
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
N/AN/AN/AN/A$1.01 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
-$12.55M-$0.38N/AN/AN/A-68.17%-60.38%9/5/2025 (Estimated)
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
-$37.88M-$46.00N/AN/AN/AN/A-293.92%-206.20%N/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$1.44M$0.822.57N/AN/AN/A-20.68%15.73%8/5/2025 (Estimated)
Synlogic, Inc. stock logo
SYBX
Synlogic
-$23.36M-$2.51N/AN/AN/AN/A10.91%7.47%8/6/2025 (Estimated)
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
-$35.04M-$0.80N/AN/AN/AN/A-90.03%-72.62%N/A

Latest NERV, ZYNE, SYBX, ANIX, and CBIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025N/A
Synlogic, Inc. stock logo
SYBX
Synlogic
-$0.13N/AN/AN/AN/AN/A
8/5/2025Q2 2025
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$0.95N/AN/AN/AN/AN/A
6/3/2025Q2 2025
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
-$0.10-$0.09+$0.01-$0.09N/AN/A
5/13/2025Q1 2025
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$1.07-$0.50+$0.57-$0.50N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
N/AN/AN/AN/AN/A
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
N/AN/AN/AN/AN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/AN/AN/AN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
N/AN/AN/AN/AN/A
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
N/A
8.89
8.89
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
N/A
2.29
2.29
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/A
9.21
9.21
Synlogic, Inc. stock logo
SYBX
Synlogic
N/A
3.68
3.68
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
N/A
3.43
3.43

Institutional Ownership

CompanyInstitutional Ownership
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
29.13%
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
75.19%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
34.56%
Synlogic, Inc. stock logo
SYBX
Synlogic
63.40%
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
11.23%
CompanyEmployeesShares OutstandingFree FloatOptionable
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
532.21 million24.06 millionOptionable
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
5019.55 million18.77 millionNo Data
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
9N/AN/ANot Optionable
Synlogic, Inc. stock logo
SYBX
Synlogic
8011.70 million11.34 millionOptionable
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
2553.94 million46.91 millionOptionable

Recent News About These Companies

Harmony Biosciences: If It Ain't Broke
US Penny Stocks To Watch In October 2024
Discover 3 US Penny Stocks With Market Caps Over $70M
GW Pharma's cannabis-derived epilepsy drug approved in EU
20 Countries With Highest Rate of Epilepsy

New MarketBeat Followers Over Time

Media Sentiment Over Time

Anixa Biosciences stock logo

Anixa Biosciences NASDAQ:ANIX

$3.36 +0.16 (+5.00%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$3.44 +0.08 (+2.35%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Crescent Biopharma stock logo

Crescent Biopharma NASDAQ:CBIO

$13.14 +1.40 (+11.93%)
As of 07/16/2025 04:00 PM Eastern

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Minerva Neurosciences stock logo

Minerva Neurosciences NASDAQ:NERV

$2.10 +0.29 (+16.07%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$2.08 -0.03 (-1.43%)
As of 04:04 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Synlogic stock logo

Synlogic NASDAQ:SYBX

$1.51 +0.19 (+14.39%)
Closing price 07/16/2025 04:00 PM Eastern
Extended Trading
$1.54 +0.02 (+1.66%)
As of 06:27 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

Zynerba Pharmaceuticals stock logo

Zynerba Pharmaceuticals NASDAQ:ZYNE

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.